Cellular Intelligence licenses Novo’s shelved Parkinson’s cell therapy programme - Pharmaceutical Technology

Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands. Novo Nordisk shuttered its cell therapy unit in October 2025, with assets now moving to new hands. The US biotech, backed by US tech tycoon Mark Zuckerberg, will advance clinical development of the programme. Credit: Gannvector/Shutterstock.com. Cellular Intelligence has licensed Novo Nordisk’s cell therapy programme for Parkinson’s disease, seven months after the Danish drugmaker wound down operations with the modality. Cellular Intelligence, which heavily relies on AI to help advance clinical candidates, acquired the global rights to the cell therapy for an undisclosed…

Source: Pharmaceutical Technology